Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Hoyos

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Nature Communications|February 28, 2025
Pan-cancer multi-omic model of LINE-1 activity reveals locus heterogeneity of retrotransposition efficiencyAlexander Solovyov, Julie M Behr, David Hoyos, et al.
Ebiomedicine|December 10, 2025
Neoantigenic properties of TP53 variants influence cancer risk in individuals with Li-Fraumeni syndromeEmilie Montellier, Olivier Manches, Jonathan Gaucher, et al.
Biorxiv : the Preprint Server for Biology|April 15, 2024
Distinct genomic and immunologic tumor evolution in germline <i>TP53</i>-driven breast cancersNabamita Boruah, David Hoyos, Renyta Moses, et al.
Nature Communications|May 21, 2026
Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancersNabamita Boruah, David Hoyos, Renyta Moses, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2023
Cancer cells co-evolve with retrotransposons to mitigate viral mimicrySiyu Sun, Jungeui Hong, Eunae You, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2022
Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung CancerAdam J Schoenfeld, Hira A Rizvi, Danish Memon, et al.
Nature|May 19, 2022
Neoantigen quality predicts immunoediting in survivors of pancreatic cancerMarta Łuksza, Zachary M Sethna, Luis A Rojas, et al.
Nature|May 11, 2022
Fundamental immune-oncogenicity trade-offs define driver mutation fitnessDavid Hoyos, Roberta Zappasodi, Isabell Schulze, et al.
Immunity|November 22, 2024
Cancer cells restrict immunogenicity of retrotransposon expression via distinct mechanismsSiyu Sun, Eunae You, Jungeui Hong, et al.
Nature|May 31, 2022
Author Correction: Fundamental immune-oncogenicity trade-offs define driver mutation fitnessDavid Hoyos, Roberta Zappasodi, Isabell Schulze, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Nature Communications|February 28, 2025
Pan-cancer multi-omic model of LINE-1 activity reveals locus heterogeneity of retrotransposition efficiencyAlexander Solovyov, Julie M Behr, David Hoyos, et al.
Ebiomedicine|December 10, 2025
Neoantigenic properties of TP53 variants influence cancer risk in individuals with Li-Fraumeni syndromeEmilie Montellier, Olivier Manches, Jonathan Gaucher, et al.
Biorxiv : the Preprint Server for Biology|April 15, 2024
Distinct genomic and immunologic tumor evolution in germline <i>TP53</i>-driven breast cancersNabamita Boruah, David Hoyos, Renyta Moses, et al.
Nature Communications|May 21, 2026
Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancersNabamita Boruah, David Hoyos, Renyta Moses, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2023
Cancer cells co-evolve with retrotransposons to mitigate viral mimicrySiyu Sun, Jungeui Hong, Eunae You, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2022
Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung CancerAdam J Schoenfeld, Hira A Rizvi, Danish Memon, et al.
Nature|May 19, 2022
Neoantigen quality predicts immunoediting in survivors of pancreatic cancerMarta Łuksza, Zachary M Sethna, Luis A Rojas, et al.
Nature|May 11, 2022
Fundamental immune-oncogenicity trade-offs define driver mutation fitnessDavid Hoyos, Roberta Zappasodi, Isabell Schulze, et al.
Immunity|November 22, 2024
Cancer cells restrict immunogenicity of retrotransposon expression via distinct mechanismsSiyu Sun, Eunae You, Jungeui Hong, et al.
Nature|May 31, 2022
Author Correction: Fundamental immune-oncogenicity trade-offs define driver mutation fitnessDavid Hoyos, Roberta Zappasodi, Isabell Schulze, et al.
Pageof 3